Home > Archive > 2014 >

Volume 33, Number 2 (May/June)

Pharmacologic Treatment of Prediabetes (pages 6-11)

Katia Cristina Portero McLellan, Ph.D., Kathleen Wyne, M.D., Ph.D., F.A.C.E., Evangelina Trejo Villagomez, Ph.D., And Willa A. Hsueh, M.D.

The International Diabetes Federation has attempted to estimate the prevalence of prediabetes, which is currently at 316 million people globally, although this is likely a dramatic underestimation. Prediabetes is a recognized risk factor for both diabetes and cardiovascular disease. Slowing the epidemic of diabetes, and its associated economic burden of microvascular and macrovascular complications, requires identification and treatment of prediabetes. This review will focus on the data using pharmacologic therapy to slow the progression from prediabetes to Type 2 diabetes.
Drug treatment

Fatty Liver Disease as a Cardiovascular Disease Risk Equivalent (pages 12-17)

Ahmed T. Mohameed, M.D., Howard P. Monsour, M.D., And Kathleen L. Wyne, M.D., Ph.D.

Current estimates indicate that at least 30% of the U.S. population has nonalcoholic fatty liver disease (NAFLD). With the increase in childhood obesity in the United States, this condition is being seen in not just adults but also children. Recent studies showing the high prevalence of NAFLD have led to the recognition that these patients are at increased risk for cardiovascular events, thus creating a clinical imperative for early diagnosis and early treatment of both NAFLD and the associated cardiovascular disease (CVD).
Complications and comorbiditiesCardiovascular disease
Complications and comorbiditiesLiver complications

Prevention of Pneumococcal and Other Diseases Through Vaccination (pages 18-19)

Vaccines play a central role in preventing serious infections in the entire population. But they are especially important for people with diabetes, who are more vulnerable to infections. Two vaccines in particular, pneumococcal and hepatitis B, are recommended specifically for people with diabetes.
Complications and comorbiditiesInsulinoma

Exenatide Versus Liraglutide (pages 20-21)

Comparing these drugs head to head gives patients and providers more data on which to base treatment decisions.
Drug treatmentIncretin mimetics

Diabetes and the Risk of Disability (pages 20-21)

A meta-analysis finds that people with diabetes have a 50% to 80% increased risk of disability.
Complications and comorbidities

“Detoxification” regimen (pages 22-23)

A patient’s health-food store is marketing a combination of herbal products to “cleanse the system.” What effect would such a product have on blood glucose control for individuals with Type 1 diabetes?
Management strategies and toolsComplementary and alternative medicine

Monogenic diabetes (pages 22-23)

What combination of symptoms, test results, and family history suggest that a person should be tested for monogenic diabetes?
Monogenic diabetes

Erectile dysfunction (pages 22-23)

What help is available for older men with Type 2 diabetes, peripheral neuropathy, low testosterone, and erectile dysfunction?
Complications and comorbiditiesSexual complications